STERIPLEX SD® Fights C. diff And Life-threatening Superbugs With Powerful Combination Of Safety And Efficacy
Now Registered Nationwide, Breakthrough Disinfectant Poised to Change Epidemic’s Course
OREM, Utah, May 13, 2013 /PRNewswire/ — sBioMed(®)( )announced today that STERIPLEX SD(®) has been registered by the U.S. Environmental Protection Agency (EPA) and is now cleared for sale in all 50 states. STERIPLEX SD is the first and only broad-spectrum, one-step cleaner/disinfectant that offers a powerful combination of safety and efficacy to eliminate healthcare associated infections (HAIs), which affect 1.7 million patients and are the cause of 99,000 American deaths annually.[i]
According to the results of a nationwide survey recently released by the Association for Professionals in Infection Control and Epidemiology, efforts to stop the spread of superbugs such as Clostridium difficile (C. diff) have increased but have resulted in little progress.
“A lot of the focus around HAIs has been on antibiotic resistance and the lack of new drugs in development to treat these superbugs, but new strategies for treating the environment are offering the most promising, long-term HAI risk reduction,” said sBioMed Chief Executive Officer Stephen P. MacMillan. “We know that the best way to prevent HAIs is by achieving total microbial kill with STERIPLEX SD, which eliminates superbugs and their future generations.”
In addition to the physical toll HAIs have taken on patients, they have cost the healthcare system between $28-33 billion annually.[ii] Under the Affordable Care Act, hospitals are no longer being reimbursed for the extra care associated with treating HAIs.
Revolutionary Efficacy and Safety Combination
Products currently being used to clean hospital rooms and healthcare equipment are either effective and highly corrosive and toxic, or not effective enough to kill resistant microbes. Institutions currently using STERIPLEX SD and its new, touchless protocol have achieved a significant drop in their HAI rates.
“The inclusion of STERIPLEX SD into our hospital’s disinfection protocol enables our staff to provide the highest quality of patient care, comfort and safety,” said Raul Lopez, director of Environmental Services, Community Hospital of the Monterey Peninsula. “Our top priority is ensuring that our patients experience the highest safety standards and that we deploy the state-of-the-art system to ensure a clean, microbe-free environment. We are excited to use a product that combines such a powerful combination of safety and efficacy while also being sustainable and environmentally friendly.”
STERIPLEX SD kills 99.999% of most germs in 30 seconds and kills 99.9999% of Clostridium difficile (C.diff) spores in only five minutes, and is proven to achieve total microbial kill against the hardest-to-kill endospores, even on the most difficult surfaces. It is the only EPA-registered broad-spectrum cleaner/disinfectant/deodorizer/sanitizer that is sporicidal, tuberculocidal, bactericidal, virucidal and fungicidal.
In a 12-month clinical trial with STERIPLEX SD in the bone marrow transplant unit of a major U.S. cancer institute, documented monthly infection rates of C. diff, MRSA, ESBL and VRE were reduced to zero within the first 30 days and remained at zero throughout the trial.
By ‘denaturing,’ or disrupting, DNA, STERIPLEX SD prevents the spread, evolution and increasing resistance of microorganisms within the healthcare environment. Studies have shown that STERIPLEX SD is far more effective in denaturing DNA than bleach while maintaining an unrivaled safety profile. Unlike other infection-control products, STERIPLEX SD does not contain bleach and is proven to be non-corrosive, non-toxic, non-fuming, non-flammable and environmentally friendly.
For more information about STERIPLEX SD, please visit www.steriplex.com.
sBioMed is a privately held Delaware Limited Liability Company with registered headquarters in Orem, Utah. sBioMed has developed a family of powerful and healthwise infection-control products that have significant applications in multiple industries and markets, and the STERIPLEX formulas were the very first disinfectant sporicides to be registered by the EPA. The technology used to develop STERIPLEX SD is similar to the company’s anthrax-fighting product, STERIPLEX Ultra, which is the only EPA-registered sporicide the federal government will use in the case of bioterror remediation.
[i] Centers for Disease Control and Prevention (US). CDC at Work, Preventing Healthcare-Associated Infections. Available from: URL: http://www.cdc.gov/washington/~cdcatWork/pdf/infections.pdf
[ii] R. Douglas Scott II, Economist Division of Healthcare Quality Promotion National Center for Preparedness, Detection, and Control of Infectious Diseases Coordinating Center for Infectious Diseases Centers for Disease Control and Prevention; The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention, March 2009